Val
—
Gro
—
Qua
—
Mom
—
Sta
—
Cap—
P/S3.10
P/E—
Fwd P/E14.21
PEG1.65
52W— – —
RSI—
Target$104.76 (+15.2%)
Beta0.57
Div3.11%
Loading chart…
RSI ()
Loading patterns…
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Signal
Trend Strength
Price Levels
52-Week Range
52W Low
—
52W High
Position in Range
—
RSI (14)
0 · Oversold
RSI 51
Overbought · 100
Signal
Neutral
EMA Price Levels
Activity & Patterns
Volume Analysis
Momentum Dashboard
Detected Patterns
7Bullish
3Bearish
0Neutral
Key Signals 2
▲ Double Bottom
Major reversal
2026-07-02 · $81.87
Two lows ~$77.53 — bullish reversal confirmed
Learn more →
▲ Double Bottom
Major reversal
2026-07-28 · $85.99
Two lows ~$78.56 — bullish reversal confirmed
Learn more →
Momentum Signals 8
▲ MACD Bullish Crossover
▲ MACD Bullish Crossover
▲ Bull Flag
▲ MACD Bullish Crossover
View overlays on the price chart via Overview tab → Pattern Overlays.
EPS — History & Forecast
Estimate
Beat
Miss
Forecast
Loading…
Revenue — History & Forecast
Revenue
Forecast
Loading…
EPS Beat Rate
100%
8/8 quarters
Wall Street Consensus
BUY
BuyHoldSell
Price Target Range
$104.76
+15.2% upside
Low $85
—
High $121
Consensus
Current price
Wall Street Analyst Ratings
Sort by
| Firm | Rating | Change | Action | Date |
|---|
Profitability
Gross Margin
65.27%Last 12 Months
Operating Margin
19.33%Last 12 Months
Return on Equity
10.65%Last 12 Months
Revenue Growth
13.70%Year over Year
Free Cash Flow
5.41BLast 12 Months
Free Cash Flow Yield
—Last 12 Months
Balance Sheet
Debt / Equity
55.37Most Recent Quarter
Current Ratio
2.07Most Recent Quarter
Cash
8.82BMost Recent Quarter
Total Debt
28.15BMost Recent Quarter
Net Debt
—Most Recent Quarter
How MDT Makes Its Money
Cash Flow Breakdown
Quarterly Metrics
| Quarter | Revenue | Rev YoY | Gross Profit | Op. Income | Net Income | Net YoY | Gross % | Op % | Net % |
|---|
Full Key Statistics
Valuation
| Market Cap | 116.35B |
| Enterprise Value | 136.30B |
| Trailing P/E | 22.57 |
| Forward P/E | 14.21 |
| PEG Ratio (5yr) | 1.65 |
| Price/Sales (ttm) | 3.10 |
| Price/Book (mrq) | 2.32 |
| EV/Revenue | 3.63 |
| EV/EBITDA | 13.10 |
Share Statistics
| Avg Vol (3m) | 8.11M |
| Shares Outstanding | 1.28B |
| Float | 1.28B |
| % Held by Insiders | 0.39% |
| % Held by Institutions | 88.66% |
| Short Ratio | 1.74 |
| Short % of Float | 0.95% |
Profitability
| Gross Margin | 65.27% |
| Operating Margin (ttm) | 19.33% |
| Profit Margin | 13.93% |
| Return on Assets (ttm) | 5.12% |
| Return on Equity (ttm) | 10.65% |
Income Statement
| Revenue (ttm) | 37.54B |
| Revenue Growth (yoy) | 13.70% |
| Gross Profit (ttm) | 24.50B |
| EBITDA | 10.41B |
| Net Income (ttm) | 5.23B |
| Diluted EPS (ttm) | 4.03 |
| EPS Growth (yoy) | 40.70% |
Balance Sheet
| Total Cash (mrq) | 8.82B |
| Total Debt (mrq) | 28.15B |
| Debt / Equity (mrq) | 55.37 |
| Current Ratio (mrq) | 2.07 |
| Book Value / Share | 39.24 |
| Operating CF (ttm) | 8.03B |
| Free Cash Flow (ttm) | 5.41B |
Trading & Dividends
| Beta (5Y) | 0.57 |
| 50-Day MA | 87.45 |
| 200-Day MA | 89.60 |
| Fwd Dividend Yield | 3.14% |
| Payout Ratio | 70.20% |
Income
Dividend Yield
3.11%Last 12 Months
Annual Rate
2.88Forward
Payout Ratio
70.20%Last 12 Months
Dividend History
Payout Ratio (Last 12 Months): 70.20%
Monthly Dividends
Ownership Breakdown
Institutional 88.66%
Insider 0.39%
Public 11.0%
Short Interest
0.95% of float
Low
Institutional 13F Holdings
Famous investors who disclosed a position in MDT in their latest SEC 13F filing.
Loading…
Insider Transactions
| Date | Insider | Role | Transaction | Shares | Price | Value |
|---|